China Dabigatran Etexilate Mesylate opanga ndi ogulitsa |CPF

Dabigatran Etexilate Mesylate

Kufotokozera Kwachidule:

Dzina la API	Chizindikiro	Kufotokozera	US DMF	EU DMF	CEP
Dabigatran Etexilate Mesylate	Anticoagulant	M'nyumba

Titumizireni imelo

Tsatanetsatane wa Zamalonda

Zolemba Zamalonda

PRODUCT DETAIL

Kufotokozera

Dabigatran etexilate mesylate (BIBR 1048MS) ndi mankhwala opangidwa pakamwa a Dabigatran.Dabigatran etexilate mesylate ali anticoagulant zotsatira ndipo ntchito prophylaxis wa venousthromboembolism ndi sitiroko chifukwa cha matenda fibrillation.

Mbiri

Kufotokozera: IC50 Mtengo: 4.5nM (Ki);10nM(Thrombin-induced platelet aggregation) [1] Dabigatran ndi chinthu chosinthika komanso chosankha, cholunjika cha thrombin inhibitor (DTI) chomwe chikukula kwambiri monga mankhwala ake opangidwa pakamwa, dabigatran etexilate.mu vitro: Dabigatran mosankha komanso mosinthika amalepheretsa thrombin yamunthu (Ki: 4.5 nM) komanso kuphatikiza kwa mapulateleti opangidwa ndi thrombin (IC(50): 10 nM), pomwe sikuwonetsa zotsatira zoletsa pazinthu zina zokongoletsa mapulateleti. -poor plasma (PPP), yoyezedwa ngati endogenous thrombin kuthekera (ETP) inhibited concentration-dependently (IC (50): 0.56 microM).Dabigatran adawonetsa zotsatira zodalira anticoagulant m'mitundu yosiyanasiyana ya m'galasi, kuwirikiza kawiri nthawi ya thromboplastin (aPTT), nthawi ya prothrombin (PT) ndi nthawi ya ecarin clotting (ECT) mu PPP yaumunthu pamagulu a 0.23, 0.83 ndi 0.18 microM, motsatira [ 1].mu vivo: Dabigatran adatalikitsa mlingo wa aPTT modalira pambuyo polowetsedwa m'mitsempha mu makoswe (0.3, 1 ndi 3 mg/kg) ndi anyani a rhesus (0.15, 0.3 ndi 0.6 mg/kg).Mlingo ndi nthawi yodalira anticoagulant zotsatira zidawonedwa ndi dabigatran etexilate yoperekedwa pakamwa kwa makoswe ozindikira (10, 20 ndi 50 mg / kg) kapena anyani a rhesus (1, 2.5 kapena 5 mg / kg), ndi zotsatira zazikulu zomwe zimawonedwa pakati pa 30 ndi 120 min pambuyo poyang'anira, motsatana [1].Odwala omwe amathandizidwa ndi dabigatran etexilate adakumana ndi zikwapu zochepa za ischemic (3.74 dabigatran etexilate vs 3.97 warfarin) ndi zochepa zophatikizira magazi m'magazi ndi zikwapu za haemorrhagic (0.43 dabigatran etexilate vs 0.99 warfarin) [20 odwala-20] pazaka 10.Kuyesa kwachipatala: Kuwunika kwa Pharmacokinetics ndi Pharmacodynamics ya Oral Dabigatran Etexilate mu Hemodialysis Odwala.Gawo 1

Kusungirako

Ufa	-20 ° C	3 zaka
	4°C	zaka 2
Mu zosungunulira	-80 ° C	6 miyezi
	-20 ° C	1 mwezi

Kuyesa Kwachipatala

Nambala ya NCT	Wothandizira	Mkhalidwe	Tsiku loyambira	Gawo
NCT02170792	Boehringer Ingelheim	Wathanzi	February 2001	Gawo 1
NCT02170974	Boehringer Ingelheim	Wathanzi	July 2004	Gawo 1
NCT02170831	Boehringer Ingelheim	Wathanzi	Meyi 1999	Gawo 1
NCT02170805	Boehringer Ingelheim	Wathanzi	Epulo 2001	Gawo 1
NCT02170610	Boehringer Ingelheim	Wathanzi	Marichi 2002	Gawo 1
NCT02170909	Boehringer Ingelheim	Wathanzi	December 2004	Gawo 1
NCT02171000	Boehringer Ingelheim	Wathanzi	Epulo 2005	Gawo 1
NCT02170844	Boehringer Ingelheim	Wathanzi	June 2004	Gawo 1
NCT02170584	Boehringer Ingelheim	Wathanzi	Januware 2001	Gawo 1
NCT02170935	Boehringer Ingelheim	Thromboembolism ya venous	Epulo 2002	Gawo 2
NCT02170636	Boehringer Ingelheim	Wathanzi	Januware 2002	Gawo 1
NCT02170766	Boehringer Ingelheim	Wathanzi	October 2000	Gawo 1
NCT02171442	Boehringer Ingelheim	Wathanzi	Epulo 2002	Gawo 1
NCT02170896	Boehringer Ingelheim	Wathanzi	October 2001	Gawo 1
NCT02173730	Boehringer Ingelheim	Wathanzi	Novembala 2002	Gawo 1
NCT02170623	Boehringer Ingelheim	Wathanzi	February 2002	Gawo 1
NCT02170116	Boehringer Ingelheim	Wathanzi	Novembala 1998	Gawo 1
NCT02170597	Boehringer Ingelheim	Wathanzi	Ogasiti 2003	Gawo 1
NCT01225822	Boehringer Ingelheim	Thromboembolism ya venous	Novembala 2002	Gawo 2
NCT02170701	Boehringer Ingelheim	Thromboembolism ya venous	October 2000	Gawo 2
NCT02170740	Boehringer Ingelheim	Wathanzi	Novembala 1999	Gawo 1
NCT02170922	Boehringer Ingelheim	Wathanzi	July 1999	Gawo 1